Company profile: Rigel Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of small-molecule drugs for autoimmune, cancer and metabolic diseases, offering REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation and TAVALISSE (fostamatinib) for adult chronic ITP; pipeline includes R289 for LR-MDS, milademetan (MDM2) for liposarcoma with Daiichi Sankyo, bemcentinib (AXL) for NSCLC with BerGenBio, and R552 (RIPK1) for rheumatoid arthritis with Eli Lilly.
Products and services
- R289: Provides an investigational small-molecule therapy in development for treating patients with lower-risk myelodysplastic syndromes (LR-MDS)
- REZLIDHIA: Offers a small-molecule therapy for adult patients with relapsed or refractory acute myeloid leukemia with a specific IDH1 mutation
- TAVALISSE: Delivers a small-molecule therapy indicated for the treatment of adult patients with chronic immune thrombocytopenia (ITP)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rigel Pharmaceuticals
Alpine Immune Sciences
HQ: United States
Website
- Description: Provider of protein-based immunotherapies for autoimmune and inflammatory diseases, using a proprietary directed evolution platform to engineer native immune proteins into multi-targeted therapeutics. Pipeline includes povetacicept (ALPN-303), a dual BAFF/APRIL antagonist, and acazicolcept (ALPN-101), a dual CD28/ICOS antagonist; conducts clinical trials on investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpine Immune Sciences company profile →
Gesynta Pharma
HQ: Sweden
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing mPGES-1–inhibiting drug candidates to reduce inflammation and pain. Pipeline includes vipoglanstat (GS-248), a non-hormonal treatment for endometriosis in phase II, and GS-073 for chronic inflammatory pain entering phase I. Research originates from Karolinska Institutet; GS-073 from AstraZeneca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gesynta Pharma company profile →
Resolvyx
HQ: United States
Website
- Description: Provider of therapeutics based on small molecule lipid mediators for the treatment of inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resolvyx company profile →
Agomab Therapeutics
HQ: Belgium
Website
- Description: Provider of molecular therapies to regenerate damaged tissues and restore organ function in fibrotic, inflammatory, autoimmune and degenerative diseases. Programs include agomAbs that stimulate repair and small-molecule ALK5 inhibitors: AGMB-129 (oral GI-restricted for fibrostenosing Crohn’s) and AGMB-447 (inhaled lung-restricted for IPF), plus HGF-mimetic full/partial MET agonist antibodies AGMB-101/102, and expanded access/compassionate use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agomab Therapeutics company profile →
Endpoint Health
HQ: United States
Website
- Description: Provider of precision immunology solutions, including targeted therapeutics tailored to patient biology for immune-mediated diseases, companion diagnostics to personalize treatment, a precision immunology ecosystem with pharma, biotech, diagnostics providers and clinical data registries, and clinical collaborations with over 60 global health systems to develop precision therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endpoint Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rigel Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rigel Pharmaceuticals
2.2 - Growth funds investing in similar companies to Rigel Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rigel Pharmaceuticals
4.2 - Public trading comparable groups for Rigel Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →